CLINICAL TRIALS CENTER FOR ALLHAT

ALLHAT是一项以实践为基础的随机临床试验 抗高血压药物治疗，在一个子集中，胆固醇- 降压疗法。4万名高危高血压患者，年龄 55岁及以上，包括很高比例的非裔美国人 被招募了。因为糖尿病和高血压经常同时发生 糖尿病高血压患者心血管疾病的发生率很高， 高比例的糖尿病患者被招募。初级阶段 该双盲抗高血压试验的目的是确定 非致命性心肌梗死和非致死性心肌梗死的联合发病率 在接受治疗的患者中，冠心病死亡率较低 赖诺普利(ACE抑制剂)、氨氯地平(钙拮抗剂)或 多沙唑嗪(α-1受体阻滞剂)与对照组相比 氯苯吡酮(利尿剂)。次要终点是全心血管系统 死亡率、重大发病率、全因死亡率和与健康有关 生活质量。脂质试验的主要目标是 确定全因死亡率是否在中等程度上较低 高胆固醇血症的男性女性患者接受胆固醇治疗- 降压药物普伐他汀(HMG CoA还原酶抑制剂)，比开放的 “常规护理”对照组。次要端点组合在一起 非致命性心肌梗死和冠心病的发病率 死亡，主要非心血管疾病的发病率和死亡率，以及健康- 相关的生活质量。随访的平均持续时间将 大约六(4.5-7.5)年。 不是使用独立资助的诊所，而是招募患者 通过办公室实践和高血压诊所 通过临床试验中心按每位患者报销。 这份合同是关于临床试验中心的。其中的一些功能 临床试验中心的工作包括协调所有数据收集， 数据存储、与研究相关的分析活动，以及 招募和培训(与NHLBI一起)合适的临床 地点和核心实验室需要进行这项研究。

ALLHAT is a practice-based, randomized clinical trial of antihypertensive pharmacologic treatment and, in a subset, cholesterol- lowering therapy. Forty thousand high-risk hypertensive patients, age 55 and older, including a high percentage of African-Americans are being recruited. Because diabetes and hypertension occur together frequently and diabetic hypertensives have high rates of cardiovascular disease, a high percentage of diabetic patients were recruited. The primary objective of the double-blind antihypertensive trial is to determine whether the combined incidence of nonfatal myocardial infarction and coronary heart disease death is lower among patients receiving lisinopril (ACE inhibitor), amlodipine (calcium antagonist), or doxazosin (alpha-1-blocker) than in a control group receiving chlorthalidone (diuretic). Secondary endpoints are total cardiovascular mortality, major morbidity, all-cause mortality and health-related quality of life. The primary objective of the lipid trial is to determine whether all-cause mortality is lower in moderately hypercholesterolemic men women patients receiving the cholesterol- lowering drug pravastatin (HMG CoA reductase inhibitor), than in an open "usual care" control group. Secondary endpoints are the combined incidence of nonfatal myocardial infarction and coronary heart disease death, major non-cardiovascular morbidity and mortality, and health- related quality of life. The average duration of follow-up will approximately 6 (4.5 - 7.5) years. Rather than using independently funded clinics, patients are recruited through office-based practices and hypertension clinics which are reimbursed through the Clinical Trials Center on a per-patient basis. This contract is for the Clinical Trials Center. Some of the functions of the Clinical Trials Center include coordinating all data collection, storage of data, analysis activities related to the study, and recruiting and training (along with the NHLBI) appropriate clinical sites and core laboratories require to conduct the study.